Cardiology – Page 15

Beyond the Backpressure: Targeting the Integrin αV-YAP-CTGF Axis to Halt Fibrosis in Congestive Hepatopathy

By MedXY 03/31/2026

This study identifies the integrin αV-YAP-CTGF axis in liver sinusoidal endothelial cells as a primary driver of fibrosis and carcinogenesis in congestive hepatopathy. By targeting this mechanosensitive pathway, researchers demonstrated a significant reduction in portal hypertension and liver damage in both murine models and human clinical samples.

Cardiology Clinical Updates news

Advancing Venous Thromboembolism Prediction: Insights from Large-Scale Plasma Proteomics and Mendelian Randomization

By MedXY 03/31/2026

This review synthesizes findings from a landmark proteomic study identifying 23 plasma proteins associated with VTE risk, highlighting novel pathways in immunity and vascular senescence while exploring causal links through Mendelian Randomization.

Cardiology Hematology-Oncology news

Beyond the Clot: Novel Proteomic Markers Reveal New Pathophysiological Pathways for Venous Thromboembolism

By MedXY 03/31/2026

A large-scale proteomic meta-analysis across five cohorts identified 15 novel plasma protein markers for venous thromboembolism, highlighting the roles of the extracellular matrix, immunity, and vascular senescence in disease risk and offering potential new targets for clinical prevention.

Cardiology news

Synergistic Risk Assessment: Coronary Artery Calcium Scoring Remains Vital in Patients with Elevated Lipoprotein(a)

By MedXY 03/30/2026

A large-scale multicohort study demonstrates that while elevated Lipoprotein(a) increases cardiovascular risk, Coronary Artery Calcium (CAC) scoring remains a powerful independent predictor of events, even in patients with high Lp(a) levels, providing essential clarity for clinical risk stratification.

Cardiology Clinical Updates Internal Medicine news

Deciphering the Clinician’s Dilemma: Determinants of Antihypertensive Treatment Intensification in Older Adults

By MedXY 03/28/2026

This review analyzes the complex factors influencing blood pressure management in older adults, highlighting how age, frailty, and digital health data shape clinician decisions and clinical inertia.

Cardiology Gastroenterology news

Targeting the Integrin αV-YAP-CTGF Axis: A New Frontier in Treating Congestive Hepatopathy and Liver Carcinogenesis

By MedXY 03/28/2026

Researchers have identified a mechanosensitive signaling pathway in liver sinusoidal endothelial cells that drives fibrosis and cancer in response to chronic congestion, offering a new therapeutic target for heart-failure-related liver disease.

Cardiology Gastroenterology news

From Pressure to Cancer: Unveiling the Integrin αV-YAP-CTGF Axis as a Therapeutic Target in Congestive Hepatopathy

By MedXY 03/28/2026

Researchers have identified a novel signaling pathway in liver sinusoidal endothelial cells (LSECs) that drives fibrosis and liver cancer in congestive hepatopathy. The study highlights the Integrin αV-YAP-CTGF axis as a critical mechanism and potential therapeutic target for patients with chronic hepatic congestion.

Cardiology Hematology-Oncology news

Beyond the Clot: Novel Proteomic Markers Redefine Venous Thromboembolism Risk

By MedXY 03/28/2026

This large-scale proteomic analysis identifies 15 novel protein markers for venous thromboembolism, offering new insights into the roles of immunity and extracellular matrix regulation in VTE pathogenesis beyond traditional coagulation pathways.

Cardiology Clinical Updates Diabetes & Endocrinology Nephrology news

The Cardiovascular-Kidney-Metabolic (CKM) Syndrome Revolution: Mapping Medication Eligibility and Multi-Systemic Benefits

By MedXY 03/28/2026

This review synthesizes recent evidence on the massive scale of CKM medication eligibility in the US, the synergistic effects of pharmacotherapy with lifestyle, and emerging neuropsychiatric benefits of GLP-1 receptor agonists.

Cardiology news

TEER vs. Medical Therapy: Redefining the Management of Atrial Functional Mitral Regurgitation

By MedXY 03/27/2026

A large-scale registry analysis demonstrates that Transcatheter Edge-to-Edge Repair (TEER) significantly reduces mortality and heart failure hospitalizations in patients with atrial functional mitral regurgitation (AFMR) compared to medical therapy, provided optimal procedural results are achieved.

Cardiology Diabetes & Endocrinology news

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

By MedXY 03/26/2026

Researchers from the ARIC study have identified five specific proteomic markers that uniquely predict heart failure risk in individuals with diabetes. These findings, including four novel proteins, suggest distinct pathophysiological pathways for diabetic cardiomyopathy and offer new targets for precision screening and therapeutic intervention.

Cardiology news

Sex-Specific Risk Thresholds in Aortic Regurgitation: Challenging the One-Size-Fits-All Approach to LV Remodeling

By MedXY 03/26/2026

A multicenter study reveals that women with moderate-severe aortic regurgitation face higher mortality risk at lower ventricular volumes than men. Findings suggest current guidelines may require revision to include sex-specific volumetric thresholds and lower linear diameter cutoffs to optimize surgical timing.

Cardiology news

Navigating the AfMR Maze: Expert Consensus and the Future of Mitral Regurgitation Diagnosis

By MedXY 03/25/2026

This article examines the debate between JACC and ESC definitions for Atrial Functional Mitral Regurgitation (AfMR), highlighting why the JACC Expert Consensus offers a more robust framework for clinical prognosis and patient classification.

Cardiology news

Breaking the Brake: How Annexin A2 Inhibition Restores Mitophagy and Salvages the Infarcted Heart

By MedXY 03/25/2026

This study identifies Annexin A2 as a critical negative regulator of PHB2-mediated mitophagy in myocardial infarction. By promoting PHB2 degradation via the TRIM29 ligase, ANXA2 exacerbates cardiac injury. Inhibiting ANXA2 restores mitochondrial homeostasis, offering a promising therapeutic avenue for heart failure.

Cardiology Clinical Updates Internal Medicine news

Redefining Gout Management: Cardiovascular Risk Reduction via Treat-to-Target Urate-Lowering Therapy

By MedXY 03/25/2026

Achieving serum urate targets <6 mg/dL (or <5 mg/dL) through Treat-to-Target (T2T) protocols significantly reduces major adverse cardiovascular events in gout patients, particularly those at high baseline risk.

Cardiology Clinical Updates Diabetes & Endocrinology news

Decoding the Diabetic Heart: Novel Proteomic Signatures of Heart Failure Risk in the ARIC Study

By MedXY 03/22/2026

A comprehensive review of the ARIC study's identification of five unique proteomic markers—four novel—that specifically predict heart failure risk in patients with diabetes, offering new insights into lipid metabolism and inflammatory pathways.

Cardiology news

Sex-Specific Risk Stratification in Aortic Regurgitation: Moving Beyond One-Size-Fits-All Thresholds

By MedXY 03/21/2026

New evidence suggests that current guidelines for aortic regurgitation may overlook sex-specific risks. A recent study proposes lower surgical thresholds for both sexes and distinct volumetric cutoffs (40 mL/m² for women, 45 mL/m² for men) to improve survival outcomes and precision in cardiac care.

Cardiology Internal Medicine news

Beyond Statins: The Evolution and Clinical Impact of PCSK9 Inhibition in Cardiovascular Risk Management

By MedXY 03/21/2026

This article explores the transformation of lipid management through PCSK9 inhibitors. From genetic discovery to landmark cardiovascular outcomes trials, we examine how monoclonal antibodies, RNA interference, and gene editing are redefining the boundaries of LDL-C reduction and patient care in atherosclerotic disease.

Cardiology Internal Medicine news

Redefining Heart Valve Disease: The Battle Over Atrial Functional Mitral Regurgitation Guidelines

By MedXY 03/21/2026

This article explores the critical differences between JACC and ESC definitions for Atrial Functional Mitral Regurgitation (AfMR), highlighting how the JACC Consensus provides a more robust prognostic framework for managing this emerging heart condition.

Cardiology news

Unlocking Mitochondrial Resilience: How Annexin A2 Inhibition Protects the Infarcted Heart

By MedXY 03/21/2026

Researchers identify Annexin A2 as a key inhibitor of mitophagy in the heart. By blocking the mitophagy receptor PHB2, ANXA2 exacerbates cardiac injury after myocardial infarction. This study demonstrates that targeting ANXA2 restores mitochondrial homeostasis and improves cardiac remodeling.